Oncology

Latest News

The investigators found that tumor mutational burden and PD-L1 expression, which have traditionally been used as indicators of immunotherapy efficacy, had little predictive value for survival in this cohort. | Image credit: Dragana Gordic - stock.adobe.com

Predictive Model Forecasts Advanced NSCLC Outcomes

By Jared Kaltwasser

August 14th 2025

The newly developed model has an area under the curve of 0.807 for predicting progression-free survival.

Dordaviprone is indicated for recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children. | Image credit: wladimir1804 - stock.adobe.com

FDA Approves Dordaviprone as First and Only Treatment for Aggressive Form of Glioma

By Rose McNulty

August 6th 2025

Gen Li, PhD, MBA, president and founder of Phesi

Real-World Data, Digital Patient Profiles Are Revolutionizing Trial Design, Patient Recruitment: Gen Li, PhD, MBA

By Pearl Steinzor
Gen Li, PhD, MBA

August 4th 2025

Value-based care. | Image Credit: irissca - stock.adobe.com

Legal Navigation Services Key to Addressing Disparities in Cancer Care

By Cameron Santoro

July 31st 2025

Radiotherapy can work synergistically with immunotherapy by reprogramming the tumor microenvironment. | Image credit: Crystallight-stock.adobe.com

Brain Radiotherapy Plus ICIs Boost Survival in SCLC With Brain Metastases

By Jared Kaltwasser

July 30th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

View All

August 18th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

August 18th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

February 1st 2018

AJMC®tv Interviews, January 2018

At the American Society of Hematology’s 59th Annual Meeting and Exposition, healthcare industry leaders sat down with The American Journal of Managed Care® to speak about what’s new and important about changes in healthcare. Access the video clips at ajmc.com/conferences/ash-2017.

February 1st 2018

Single-Agent Ibrutinib Promising in MCL and CLL, Improves Patient Well-Being

Surabhi Dangi-Garimella, PhD

Coverage from the 59th Annual Meeting and Exposition of the American Society of Hematology, December 9-12, 2017.

February 1st 2018

Biosimilars Update

Coverage from the 59th Annual Meeting and Exposition of the American Society of Hematology, December 9-12, 2017.

January 31st 2018

CAR T Progress: Global Submissions for Kymriah, 42% Ongoing Response With Yescarta in ZUMA-1 Patients

Surabhi Dangi-Garimella, PhD

Coverage from the 59th Annual Meeting and Exposition of the American Society of Hematology, December 9-12, 2017.

January 31st 2018

Study Shows Interactive Tool Increases Patient Knowledge of Breast Cancer Treatment Options

Samantha DiGrande

The Cancer Surveillance and Outcomes Research Team at the University of Michigan Comprehensive Cancer Center recently developed an interactive online tool to help patients with breast cancer understand their treatment options more fully.

January 31st 2018

Dr Roger Brito on When Providers Should Be Involved in Reimbursement Model Development

Providers should be involved in new reimbursement model development from day 1, said Roger Brito, DO, national director for oncology, Aetna.

January 31st 2018

CAR T-Cell Therapy Named ASCO's Advance of the Year

Jaime Rosenberg

Chimeric antigen receptor (CAR) T-cell therapy has been named the Advance of the Year in ASCO’s Clinical Cancer Advances 2018. According to the annual report, CAR T-cell therapy is “poised to transform the outlook for children and adults with certain otherwise incurable cancers."

January 30th 2018

Analysis Shows Majority of Hospitals Will See Payment Increases Despite 340B Payment Cuts

Jaime Rosenberg

As a result of the Medicare Outpatient Prospective Payment System rule that took effect on January 1, 85% of 340B hospitals will see net payment increases in 2018. Rural hospitals will reap the largest benefits, according to an analysis conducted by Avalere and commissioned by Community Oncology Alliance.

January 30th 2018

Nat Turner: Data Can Disrupt Clinical Research and Improve Patient Care

Nat Turner, co-founder and CEO of Flatiron Health, explains how data can be used for finding potential patients to be included in clinical trials.

January 30th 2018

Scientists Develop Tool to Analyze Links Between Lifestyle Choices and Certain Cancers

Kaitlynn Ely

A team of 20 scientists in the fields of informatics, statistics, epidemiology, systematic reviews, cancer biology, and nutrition have developed a tool that will assess the links in published human studies between lifestyle factors and cancer.

January 30th 2018

Using Health IT to Increase Medication Adherence and Enhance Precision Medicine

Jaime Rosenberg

As health information technology (IT) tools are continually being introduced into the healthcare sphere, organizations are utilizing these tools to optimize care coordination, patient experience, and patient outcomes. Today, 2 organizations join us; 1 uses a 2-way text messaging platform to support patients and increase medication adherence, and the other is teaming up with a pharmaceutical company to develop health IT solutions in order to enhance precision medicine in oncology.

January 29th 2018

Oncologists Overcome Hurdles to Deliver Cancer Care in Puerto Rico

Allison Inserro

Even though much more remains to be done on an island where half of its US residents still lack power, the situation is improving for cancer patients in Puerto Rico, doctors and organizations said recently in interviews with The American Journal of Managed Care®. In Puerto Rico, more than 75% of the cancer care is delivered in the community, not hospitals.

January 29th 2018

Dr Mark Fendrick: How Expensive Therapies Fit Into VBID for Oncology

When a drug becomes first-line, I would like to think that as a clinician I would have access to that, but most importantly that my patients would not have to have a bake sale or take out a second mortgage on their homes to get therapies that are designed specifically for them, said A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design at the University of Michigan.

January 28th 2018

ASCO Provides CMS Recommendations on Revisions to Part D

Kaitlynn Ely

The American Society of Clinical Oncology (ASCO) recommends that CMS guard cancer patients from high out-of-pocket costs that will impede patient access to life-extending cancer drugs, according to the society’s comments regarding proposed financial revisions to the Medicare Prescription Drug Benefit Program (Part D).

January 27th 2018

Gut Microbiome Diversity Associated With Blood Infections in Pediatric Patients With Cancer

Laura Joszt, MA

Every year, central lines are associated with causing blood infections in an estimated 400,000 patients with cancer. However, new research has found that changes in the microbiome may be responsible for some or many of the infections usually attributed to central lines.

January 27th 2018

Bo Gamble Explains How COA Helps Practices Prepare for OCM

Bo Gamble, director of Strategic Practice Initiatives at the Community Oncology Alliance (COA), explains how COA plays a role in supporting practices in preparing for Oncology Care Model.

January 26th 2018

Via Oncology Acquisition Positions Pathway Provider for Growth

Mary Caffrey

Via Pathways covers more than 2000 different patient representations in cancer care.

January 26th 2018

Study Notes Racial Differences in Risk of Recurrence Among Patients With Breast Cancer

Kaitlynn Ely

Non-Hispanic black women diagnosed with HER2-negative, lymph node-negative breast cancer who had recurrence score testing had higher estimated risks of distant recurrence than their non-Hispanic white counterparts.

January 25th 2018

High Cost Sharing Associated With Reduced Access to Targeted Therapies for Patients With mRCC

Jaime Rosenberg

High cost sharing is associated with reduced and/or delayed access to targeted therapies under Medicare Part D for patients with metastatic renal cell carcinoma, suggesting that financial barriers play a significant role in treatment decisions, according to a study published in Cancer Medicine.

January 24th 2018

Patients Prefer End-of-Life Care in Their Location of Choice

Kaitlynn Ely

Patients diagnosed with cancer want their doctors to ask them their desire location for end-of-life (EOL) care, according to a recent study published in the Journal of the National Comprehensive Cancer Network.

January 24th 2018

Dr Peter Aran on What Oncologists Implementing OCM Can Learn From Existing Models

Over the next years, these spheres (ACOs, primary care, and oncology) that are going on in CMMI need to be coalesced together so that when we have learning collaboratives, not only do we have learning collaboratives within each of these spheres, but we learn from each other in these similar projects, said Peter Aran, MD, medical director of Population Health Management at Blue Cross Blue Shield of Oklahoma.

$Kyprolis Label Gets Updated Improved Survival Data for Patients With Relapsed/Refractory MM$

January 22nd 2018

Kyprolis Label Gets Updated Improved Survival Data for Patients With Relapsed/Refractory MM

Laura Joszt, MA

The FDA has approved a supplemental New Drug Application to add new overall survival (OS) data for carfilzomib (Kyprolis). The label will now show that carfilzomib and dexamethasone reduced the risk of death by 21% and increased OS by 7.6 months compared with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (MM).

January 22nd 2018

The Fallacy of Estimating OCM Target Prices

Darcie Hurteau

Estimating episodic target prices for each patient in the Oncology Care Model (OCM) can be challenging and time consuming. Applying that time to quality-focused care management tactics, based on observed utilization and patient outcomes, may wind up being more valuable, and help to reduce unnecessary spending.

January 20th 2018

Treating Patients With Melanoma With Targeted Therapies Before Surgery Can Delay Relapse

Samantha DiGrande

Researchers at The University of Texas MD Anderson Cancer Center recently reported in Lancet Oncology that a pair of targeted therapies given before and after surgery for melanoma produced a 6-fold increase in time to progression of the disease, compared with standard-of-care surgery for patients with stage 3 melanoma.

January 20th 2018

Podcast: This Week in Managed Care—Kentucky's Medicaid Work Requirement and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

January 20th 2018

Dr Roger Brito Discusses Implementing Alternative Payment Models and Its Challenges

Aetna is focusing on the healthcare triangle (patients, providers, and payers) and connecting those lines, said Roger Brito, DO, national director for oncology, Aetna.

January 19th 2018

This Week in Managed Care: January 19, 2018

This week in managed care, the top stories included the announcement that Kentucky is the first state approved to require patients work to receive Medicaid benefits; FDA Commissioner Scott Gottlieb, MD, reveals a new program to improve clinical trial transparency; research finds the worst cases of attention-deficit/hyperactivity disorder could lower life expectancy.

January 19th 2018

Risk-Targeted Lung Cancer Screening Shows Modest Benefits

Samantha DiGrande

Although risk targeting may improve screening efficiency in terms of early lung cancer mortality per person screened, the gains in efficiency are modest in terms of life-years, quality-adjusted life-years, and cost-effectiveness, according to a study recently published in Annals of Internal Medicine.

January 19th 2018

Terrill Jordan Discusses the Process of Customizing an EMR to Adapt to OCM

In order to adapt to the Oncology Care Model (OCM), Regional Cancer Care Associates had to undergo the process of adjusting and customizing its electronic medical records, explained CEO Terrill Jordan.

January 19th 2018

Horizon, RCCA Launch Pilot to Close Care Gaps Between Cancer Treatments

Mary Caffrey

New Jersey's largest payer will track a host of measures, including some that will evaluate the quality of end-of-life care.

...

59 60 61 62 63 64 65 66 67

...

187 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions